Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 1, 2006, Pages 25-30

  Khor, Li Yan ^a   DeSilvio, Michelle ^b   Li, Rile ^c   McDonnell, Timothy J ^d   Hammond, M Elizabeth H ^e   Sause, William T ^e   Pilepich, Miljenko V ^f   Okunieff, Paul ^g   Sandler, Howard M ^h   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e LDS HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Androgen Deprivation; Bax; Bcl 2; Radiation Therapy

Indexed keywords

BIOMARKERS; CYTOLOGY; DIAGNOSIS; ONCOLOGY; PROTEINS; TISSUE; TUMORS;

ANDROGEN DEPRIVATION; BAX; BCL-2; RADIATION THERAPY ONCOLOGY GROUP (RTOG);

RADIOTHERAPY;

ANTIANDROGEN; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOLOGY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR CELL; UNIVARIATE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BCL-2-ASSOCIATED X PROTEIN; HUMANS; MALE; MULTICENTER STUDIES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33746827937     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.03.056     Document Type: Article

References (32)

1. Reed J.C. Bcl-2 family proteins. Oncogene 17 (1998) 3225-3236
2. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
3. Bylund A., Stattin P., Widmark A., et al. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol 49 (1998) 143-148
4. Mackey T.J., Borkowski A., Amin P., et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52 (1998) 1085-1090
5. Scherr D.S., Vaughan Jr. E.D., Wei J., et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162 (1999) 12-16 discussion 16-17
6. Rosser C.J., Reyes A.O., Vakar-Lopez F., et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56 (2003) 1-6
7. Pollack A., Cowen D., Troncoso P., et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Ki-67, bcl-2, bax, and bcl-x. Cancer 97 (2003) 1630-1638
8. Szostak M.J., Kaur P., Amin P., et al. Apoptosis and bcl-2 expression in prostate cancer. Significance in clinical outcome after brachytherapy. J Urol 165 (2001) 2126-2130
9. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 (1992) 6940-6944
10. Tsuji M., Murakami Y., Kanayama H., et al. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer. Effect of neoadjuvant hormonal therapy. Br J Urol 81 (1998) 116-121
11. Paterson R.F., Gleave M.E., Jones E.C., et al. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 3 (1999) 277-286
12. Zellweger T., Ninck C., Mirlacher M., et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55 (2003) 20-29
13. Colombel M., Symmans F., Gil S., et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143 (1993) 390-400
14. Szende B., Romics I., Torda I., et al. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. Urol Int 63 (1999) 115-119
15. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
16. Grignon D.J., Caplan R., Sarkar F.H., et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma. A study based on RTOG 8610. J Natl Cancer Inst 89 (1997) 158-165
17. Pollack A., Grignon D.J., Heydon K.H., et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade. An analysis of RTOG 8610. J Clin Oncol 21 (2003) 1238-1248
18. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
19. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), Wiley, New York
20. Cox D. Regression Models and life tables. J Royal Stat Soc 34 (1972) 187-229
21. Raffo A.J., Perlman H., Chen M.W., et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55 (1995) 4438-4445
22. Theodorescu D., Broder S.R., Boyd J.C., et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158 (1997) 131-137
23. Keshgegian A.A., Johnston E., and Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110 (1998) 443-449
24. Moul J.W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 35 (1999) 399-407
25. Fonseca G.N., Srougi M., Leite K.R., et al. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J 122 (2004) 124-127
26. Cesinaro A.M., Migaldi M., Ferrari G., et al. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy. Oncol Res 12 (2000) 43-49
27. Di Lorenzo G., De Placido S., Autorino R., et al. Expression of biomarkers modulating prostate cancer progression. Implications in the treatment of the disease. Prostate Cancer Prostatic Dis 8 (2005) 54-59
28. Amirghofran Z., Monabati A., and Gholijani N. Apoptosis in prostate cancer. bax correlation with stage. Int J Urol 12 (2005) 340-345
29. Matsuura H., Hayashi N., Kawamura J., et al. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation. Eur Urol 37 (2000) 212-217
30. Grossfeld G.D., Olumi A.F., Connolly J.A., et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 159 (1998) 1437-1443
31. Chakravarti A., Heydon K., Wu C.L., et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer. An analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol 21 (2003) 3328-3334
32. Li R., Heydon K., Hammond M.E., et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy. An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res 10 (2004) 4118-4124